Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 2, 2004, Pages 209-217

  Sciveres, M ^a   Caprai, S ^a   Palla, G ^a   Ughi, C ^a   Maggiore, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; STEROID;

ADOLESCENT; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CATARACT; CHILD; CHOLANGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GIANT CELL; GIANT CELL HEPATITIS; GINGIVA HYPERTROPHY; GROWTH RETARDATION; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERTRICHOSIS; INFANT; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; MALE; MEDICAL RECORD; MENTAL DISEASE; MOON FACE; OBESITY; OSTEOPOROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; MALE; TREATMENT OUTCOME;

EID: 0842330083     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01754.x     Document Type: Review

References (55)

1. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Arch Dis Child 1996; 74: 2-5.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med 1996; 334: 897-903.
3. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000; 32(Suppl. 1): 181-97.
4. El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987; 92: 1226-35.
5. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 10-5.
6. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-8.
7. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: 16-year prospective study. Hepatology 2001; 33: 544-53.
8. Angulo P, Maor-Kendler Y, Lindor KD. Small duct primary sclerosing cholangitis: a long term follow-up study. Hepatology 2002; 35: 1494-500.
9. Bernard O, Hadchouel M, Scotto J, Odièvre M, Alagille D. Severe giant cell hepatitis with autoimmune hemolytic anemia in early childhood. J Pediatr 1981; 99: 704-11.
10. Vegnente A, Larcher VF, Mowat AP, Portmann B, Williams R. Duration of chronic active hepatitis and development of cirrhosis. Arch Dis Child 1984; 59: 330-5.
11. Vajro P, Hadchouel P, Hadchouel M, Bernard O, Alagille D. Incidence of cirrhosis in children with chronic hepatitis. J Pediatr 1990; 117: 392-6.
12. Maggiore G, Bernard O, Hadchouel M, Hadchouel P, Odièvre M, Alagille D. Treatment of autoimmune chronic active hepatitis in childhood. J Pediatr 1984; 104: 839-43.
13. Maggiore G, Bernard O, Homberg JC, et al. Liver disease associated with anti-liver-kidney microsome antibody in children. J Pediatr 1986; 108: 399-404.
14. Maggiore G, Veber F, Bernard O, et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993; 17: 376-81.
15. Gregorio GV, Portman B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-7.
16. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticoid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
17. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
18. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-83.
19. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
20. Czaja AJ. Drug therapy in the management of the type I autoimmune hepatitis. Drugs 1999; 57: 49-68.
21. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 1996; 80: 973-94.
22. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990; 116: 280-2.
23. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid treated autoimmune hepatitis. Hepatology 1992; 15: 215-21.
24. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
25. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-23.
26. Van Thiel DK, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
27. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 AIH with methotrexate. J Hepatol 1998; 29: 990-3.
28. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
29. Lie TS. Erfolgreiche Behandlung der chronisch-aktiven hepatitis mit Cyclosporin-A. Munch Med Wochenschr 1984; 126: 693-4.
30. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-55.
31. Hyams JS, Ballow M, Leichtner AM. Cyclosporin treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3.
32. Person JL, McHutchinson JC, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 317-20.
33. Sherman KE, Narkewicz M, Pinto PC. Cyclosporin in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
34. Senturk H. Treatment of corticosteroid-azathioprine resistant autoimmune hepatitis with cyclosporin A. Indian J Gastroenterol 1995; 14: 110-1.
35. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
36. Launay V, Gottrand F, Michaud L, Masy E, Turck D, Farriaux JP. Traitement par la ciclosporine d'une épatite auto-immune révélée par une insuffisance hépatocellulaire aiguë. Arch Pediatr 1997; 4: 40-3.
37. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8.
38. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-7.
39. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 111-4.
40. Perraux F, Zenary D, Capron F, Trioche P, Odièvre M, Labrune P. Azathioprine-induced lung toxicity and efficacy of cyclosporine A in a young girl with type 2 autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2000; 31: 190-2.
41. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-7.
42. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIR, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349: 825-32.
43. Johnson PJ, McFarlane IG. Meeting report: International AIH Group. Hepatology 1993; 18: 998-1005.
44. Alvarez F, Berg PA, Blanchi FB, et al. International Autoimmune Hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
45. Johnston A, Holt DW. Bioequivalence criteria for cyclosporine. Transplant Proc 1999; 31: 1649-53.
46. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435-56.
47. Minuk GY. Cyclosporin A in non-transplant-related liver diseases. Am J Gastroenterol 1989; 84: 1345-50.
48. Treem W, Hyams JS. Cyclosporine therapy for gastrointestinal disease. J Pediatr Gastroenterol Nutr 1994; 18: 270-8.
49. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436-43.
50. Morris PJ. Ciclosporin. Transplantation 1981; 32: 349-54.
51. Lobo Yeo A, Alviggi L, Mieli-Vergani G, Portmann B, Mowat AP, Vergani D. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol 1987; 67: 95-104.
52. Mieli-Vergani G, Lobo-Yeo A, McFarlane BM, McFarlane IG, Mowat AP, Vergani D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis. Hepatology 1989; 9: 198-203.
53. Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1999; 13: 33-8.
54. Gleeson JG, duPlessis AJ, Barnes PD, Riviello JJ Jr. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: clinical features and risk of seizure recurrence. J Child Neurol 1998; 13: 336-44.
55. Vilca Melendez H, Rela M, Baker AJ, et al. Liver transplant for giant cell hepatitis with autoimmune haemolytic anemia. Arch Dis Child 1997; 77: 249-51.